Photocure $PHO.OL OSL:PHO presented Q2 2019 numbers today, with most numbers landing very close to expectations.
Webcast: webtv.hegnar.no
Press release: newsweb.oslobors.no
Armchair Healthcare podcast interview with CEO Dan Schneider: twitter.com
Investors are eagerly awaiting Photocures OSL:PHO Q2 2019 report to get a more indepth description of the recently announced Cevira partnership deal.
Also key is the information about the current growth rate on Cysview sales in US.
NOK 60-64 is a key level of expected resistance, as it is where the share price peaked in 2018, while a negative reaction could...
Photocure OSL:PHO today released news of a outlicensing of the Cevira franchise for commercialization, giving the stock a boost, possibly regaining foothold above the SMA50 and SMA200.
Press release
photocure.com
Photocure $PHO.OL approaching relevant resistance levels and a breakout to the upside could easily be triggered as the market cap of the company is still low.
Recent Edison analysis quote:
" Phenomenal US growth
Q418 sales in the US increased 81% to NOK18.4m and are up 50% over the course of 2018 with a clear acceleration in the second half of the year. Unit...
Photocure $PHO.OL stock reacted with a correction after a overblown rally ahead of Q4 2018 report, but found firm footing and looks set to restart positive trend.
As mentioned in an earlier Idea ( ), the Q4 report represented a substantial risk for a downwards reaction after a recent surge in the share price.
At the new price level around NOK 41 the stock is much more attractively priced, and this could be the time to move in for new investors.
Photocure stock reacted with a heavy (overdone?) correction after the Q3 report, but has recovered nicely in later weeks.
As mentioned in an earlier TradingView analysis ( ), NOK 36 and downwards presented a very good buying opportunity, which culminated when the correction bottomed at NOK 32,5 which was a very solid resistance upwards for a long time.
Entry at...
